Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity

Trial Profile

Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 03 Jan 2018

At a glance

  • Drugs Durvalumab (Primary) ; Mocetinostat (Primary)
  • Indications Squamous cell cancer
  • Focus Pharmacodynamics
  • Acronyms PRIMED-001
  • Most Recent Events

    • 27 Dec 2017 Planned End Date changed from 1 Jan 2020 to 21 Dec 2017.
    • 27 Dec 2017 Planned primary completion date changed from 1 Jan 2018 to 21 Dec 2017.
    • 27 Dec 2017 Planned initiation date changed from 1 Jan 2017 to 10 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top